Government price setting policies like Most Favored Nation are a bad deal for American patients. The “Foreign First Pricing” ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Tremfya (guselkumab) (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC).

California’s BioMarin Pharmaceutical is to acquire Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of approximately $270 million.